Cerebral cavernous malformation (CCM) is a genetic, cerebrovascular disease. Familial CCM is caused by genetic mutations in KRIT1, CCM2, or PDCD10. Disease onset is earlier and more severe in individuals with PDCD10 mutations. Recent studies have shown that lesions arise from excess mitogen-activated protein kinase kinase kinase 3 (MEKK3) signaling downstream of Toll-like receptor 4 (TLR4) stimulation by lipopolysaccharide derived from the gut microbiome. These findings suggest a gut-brain CCM disease axis but fail to define it or explain the poor prognosis of patients with PDCD10 mutations. Here, we demonstrate that the gut barrier is a primary determinant of CCM disease course, independent of microbiome configuration, that explains the increased severity of CCM disease associated with PDCD10 deficiency. Chemical disruption of the gut barrier with dextran sulfate sodium augments CCM formation in a mouse model, as does genetic loss of Pdcd10, but not Krit1, in gut epithelial cells. Loss of gut epithelial Pdcd10 results in disruption of the colonic mucosal barrier. Accordingly, loss of Mucin-2 or exposure to dietary emulsifiers that reduce the mucus barrier increases CCM burden analogous to loss of Pdcd10 in the gut epithelium. Last, we show that treatment with dexamethasone potently inhibits CCM formation in mice because of the combined effect of action at both brain endothelial cells and gut epithelial cells. These studies define a gut-brain disease axis in an experimental model of CCM in which a single gene is required for two critical components: gut epithelial function and brain endothelial signaling.
INTRODUCTION
A gut-brain axis has been implicated in a large number of diseases, including stroke (1, 2) , dementia (3), Parkinson's disease (4) , metabolic disorders such as diabetes (5, 6) , and gastrointestinal diseases such as inflammatory bowel disease (7) . Such pathogenic circuits hold the promise of treating diseases in relatively inaccessible sites such as the brain through manipulation of more accessible sites such as the gut or combining gut and brain targets for more effective therapies, but such translation requires clear definition of the pathway between organs. Numerous mechanisms have been proposed to explain connections between the gut and brain, including microbiota-generated metabolites that impact brain function, effects of the gut microbiome on local immune cells that may then travel to the brain, and direct communication between the gut and brain mediated by the nervous system or circulating factors [reviewed in (8) (9) (10) ]. However, for most of these diseases, a clear molecular and cellular basis for a gut-brain axis remains elusive because of the difficulty of demonstrating cause and effect between events occurring at two different sites. Leveraging the discovery of gut-brain disease axes to new therapies requires a better understanding of such relationships.
Cerebral cavernous malformation (CCM) is a vascular disease that predominantly affects the brain and is a common cause of hemorrhagic stroke and seizure (11) . Standard of care remains symptom management and neurosurgical resection-there remains no diseasemodifying medical therapy (12) . CCMs arise because of loss-of-function mutations in three genes, KRIT1 [also known as (aka) CCM1], CCM2, and PDCD10 (aka CCM3), that encode components of a single, hetero trimeric, adaptor protein complex. This "CCM complex" binds and negatively regulates the mitogen-activated protein kinase kinase kinase 3 (MEKK3 aka MAP3K3) in endothelial cells through a direct interaction between CCM2 and MEKK3 (13) (14) (15) (16) (17) . Familial CCM disease arises because of germline, heterozygous loss of function mutations in any of the three CCM genes, but clinical studies have demonstrated that individuals with PDCD10 mutations develop disease decades earlier than those with KRIT1 or CCM2 mutations and are more likely to suffer disabling brain hemorrhage and stroke (18, 19) . Recent studies demonstrated that lipopolysaccharide (LPS) derived from Gram-negative bacteria (GNB) in the gut microbiome drives CCM disease by activating Toll-like receptor 4 (TLR4) and MEKK3 signaling in brain endothelial cells (20) . These findings support a gut-brain axis in CCM disease, but it remains unclear how LPS from the gut lumen reaches TLR4 receptors in the brain vasculature and which steps in this journey control pathogenesis.
In the present study, we identified the gut barrier as a critical component of the CCM gutbrain axis that bridges the intestinal microbiome and the brain endothelium during disease pathogenesis. We demonstrated that programmed cell death protein 10 (PDCD10)-dependent changes in the colonic gut barrier underlie the clinical observation that germline heterozygosity of PDCD10 confers a more severe form of CCM disease than germline heterozygosity of KRIT1 or CCM2. We also found that chronic oral intake of P80, a dietary emulsifier present in preserved foods, disrupts the mucus barrier and accelerates CCM formation in a preclinical mouse disease model without altering the gut microbiome. Last, we demonstrated that dexamethasone potently blocked CCM formation in mice because of dual effects in brain endothelial cells and gut epithelial cells, highlighting the translational value of defining a gut-brain disease axis at the molecular and cellular levels.
RESULTS

CCM disease genes are not distinguished by their effects on mouse brain endothelial cell signaling or the human gut microbiome
CCMs arise because of loss of negative regulation of MEKK3 signaling in brain endothelial cells [compartment no. 1 in fig. S1A and (21) ]. We have recently demonstrated that MEKK3 signaling in brain endothelial cells is stimulated by TLR4 receptors that respond to LPS derived from GNB in the gut microbiome [compartment no. 2 in fig. S1A and (20) ], predicting that LPS must cross the gut barrier and enter the blood to drive CCM formation (compartment no. 3 in fig. S1A ). Clinical studies have revealed that CCM disease associated with mutations in PDCD10 presents decades earlier than that associated with KRIT1 or CCM2 mutations and is associated with larger lesions and greater incidence of symptomatic cerebral hemorrhage (18, 19) , an observation not explained by known protein-specific differences in CCM complex function or regulation of the gut microbiome (13) (14) (15) 22) .
To determine why PDCD10 familial disease is particularly severe, we first tested whether the requirement for PDCD10 differs from those of Krev interaction trapped protein 1 (KRIT1) or CCM2 at the levels of brain endothelial MEKK3 signaling or the gut microbiome.
To study CCM formation in vivo, we used an established neonatal mouse model that entails brain endothelial cell-specific deletion of Pdcd10 using the Slco1c1(BAC)-CreERT2 (iBECre;Pdcd10 fl/fl , "inducible brain endothelial Cre") 1 day after birth (P1) (fig. S1B) (23) . iBECre;Pdcd10 fl/fl mice exhibited CCM lesions with gain of endothelial Kruppel-like factor 4 (KLF4) expression, a downstream hallmark of elevated endothelial MEKK3 signaling that we, and others, have previously identified in Krit1 and Ccm2 mouse lesions and human CCMs (fig. S1, C to H) (13, 24, 25) . Similar to analogous genetic rescue experiments using Krit1 and Ccm2 animals, haploinsufficiency of MEKK3 in Pdcd10 littermates resulted in an 80% reduction in lesion volume at P10 assessed visually and through blinded x-ray microcomputed tomography (microCT) imaging of the entire mouse brain (Fig. 1, A and B) (13, 26, 27) . These results indicate that the role of PDCD10 in regulation of endothelial MEKK3 signaling is similar in magnitude to those of KRIT1 and CCM2 and suggest that the basis for more severe PDCD10-associated disease is likely to be an unidentified role for PDCD10 in other cell types or the gut microbiome.
Using the neonatal mouse CCM model, we recently demonstrated that the composition of the gut microbiome plays a vital role in lesion formation, with animals harboring greater numbers of GNB in the colon exhibiting greater CCM lesion formation (fig. S1A, compartment no. 2) (20) . To test whether patients with PDCD10mediated CCM might exhibit more aggressive disease due to PDCD10associated changes in the microbiome, we performed 16S ribosomal RNA (rRNA) gene sequencing of bacterial DNA extracted from the feces of 75 patients with genotyped CCM with detectable lesions using magnetic resonance imaging and compared these samples to 29 healthy volunteers from multiple clinical sites in the United States (table S1) (28) . A permutational multivariate analysis of variance (PERMANOVA) test on weighted UniFrac distances revealed a significant (P = 0.002) separation of the microbiome communities in patients with CCM disease and those in control individuals (Fig. 1C ). Fitting linear models for logit-transformed relative abundances of commonly present bacterial taxa revealed that Gram-negative Bacteroides were more abundant in individuals with CCM disease than in controls ( Fig. 1D ), whereas Gram-positive Lachnospiraceae were less abundant (fig. S1I). Individuals with familial PDCD10 disease did not exhibit microbiomes different from those with familial KRIT1 or CCM2 disease, either globally ( Fig. 1E ) or with respect to changes in Gram-negative Bacteroides or Gram-positive Lachnospiraceae species ( Fig. 1F and fig. S1J ). Although conclusions drawn from these data are limited by the relatively small sample size and biased toward symptomatic CCM disease, they support the concept that environmental factors dominate over host genetics to alter gut microbial ecology (29) . Together, our mouse genetic and human microbiome studies suggest that the basis for a more aggressive clinical course in familial PDCD10 disease is neither a unique signaling role in brain endothelial cells nor a specific effect on the gut microbiome and therefore might reflect a previously unrecognized role for PDCD10 in the intervening gut barrier.
Chemical disruption of the gut barrier accelerates CCM formation in mice
To test whether disruption of the gut barrier worsens CCM disease, we combined the dextran sulfate sodium (DSS) colitis and neonatal CCM mouse models. As previously described (13) , to initiate the neonatal CCM model, we induced endothelial cell-specific deletion of Krit1 at P1 using the Cdh5(PAC)-CreERT2 (iECre;Krit1 fl/fl , "inducible endothelial Cre"). Starting at P10, 2.5% DSS was orally administered once daily for 5 days, resulting in varying degrees of colitis ranging from epithelial thickening and crypt abscesses to complete erosion of the colonic epithelium at P21, with colitis observed in five animals treated with DSS and no colitis in four controls (P < 0.05; Fig. 2, A and B ). About 50% of neonatal animals administered DSS did not survive to P21 (likely a result of DSS effects and lethality associated with gavaging neonatal mice), but survivors (20 of 45 total animals) exhibited an approximate twofold increase in CCM volume compared to littermate, vehicletreated animals (Fig. 2 , C and D).
We previously characterized distinct Krit1 and Ccm2 mouse colonies that are respectively resistant and susceptible to CCM formation because of qualitative differences in the gut microbiome (20) . Susceptible, vehicle-treated iECre;Krit1 fl/fl animals spontaneously developed appreciable lesion volume ( 
Gut epithelial loss of PDCD10 but not KRIT1 accelerates CCM lesion formation
The exacerbation of CCM formation by DSS treatment identified the gut barrier as a potentially rate-limiting mechanism of disease pathogenesis. Although the gut barrier is a complex, multicellular system, its primary component is the gut epithelium. Analysis of single-cell gene expression in intestinal epithelial cells (IECs) revealed broad transcription of Krit1, Ccm2, and Pdcd10 across cell types (fig. S2). We therefore hypothesized that PDCD10 might play a role in gut barrier integrity distinct from that of KRIT1 and CCM2. To study the role of IEC PDCD10 in the context of CCM disease, we compared CCM formation in animals with both inducible brain endothelial cell deletion (iBECre) at P1 and constitutive IEC deletion (Villin1-Cre, "VilCre") of Pdcd10 (iBECre;VilCre;Pdcd10 fl/fl ), to littermates with only inducible brain endothelial cell deletion of Pdcd10 (iBECre;Pdcd10 fl/fl ). Loss of IEC Pdcd10 resulted in a twofold increase in lesion burden by P21 ( Fig. 3, A and B ). To determine whether PDCD10 plays a specific role in IECs during CCM formation relative to the other CCM genes, we performed the analogous Krit1 experiment. Loss of IEC Krit1 had no effect on lesion formation (Fig. 3 , C and D).
A notable clinical aspect of familial PDCD10 disease is the high rate of cerebral hemorrhage compared with familial KRIT1 or CCM2 disease (19) . Histologic examination of iBECre;VilCre;Pdcd10 fl/fl mouse brains at P21 revealed both large CCM lesions in the white matter of the cerebellum and numerous sites of perilesional hemorrhage ( Fig. 3E and fig. S3A ). Although large, multicavernous lesions were also observed in iBECre;Pdcd10 fl/fl brains, after deletion of Pdcd10 solely in the brain endothelium ( Fig. 3F and fig. S3A ), no perilesional hemorrhage was observed, consistent with prior studies of the neonatal CCM model (30) . Hemorrhage was not observed in either animals with loss of only a single Pdcd10 allele in the brain endothelium and IECs, animals with complete loss of Pdcd10 only in IECs ( Fig. 3G and fig. S3 , B to E), or in either iECre;VilCre;Krit1 fl/fl or iECre;Krit1 fl/fl mouse brains at P21 (Fig. 3, H and I, and fig. S3A ). These findings identify a role for PDCD10 in the gut epithelium during CCM formation in mice distinct from that of KRIT1.
Loss of gut epithelial PDCD10 but not KRIT1, CCM2, or MEKK3 results in loss of the colonic mucus layer
Because most GNB and GNB-derived LPS reside in the colon, to understand the role of PDCD10 in IECs during CCM formation, we analyzed the colons of the same iBECre;Pdcd10 fl/fl and iBECre;VilCre;Pdcd10 fl/fl animals shown in Fig. 3 (Fig. 4A ). Because individuals with familial PDCD10 disease are germline heterozygous, we also analyzed colons from littermate iBECre;VilCre;Pdcd10 fl/+ animals ( Fig. 4A , middle). A major component of the colonic gut barrier is the mucus layer, produced by goblet cells, that physically separates gut bacteria from the gut epithelium (31) , and an initial event in DSS-associated colitis is disruption of the mucus barrier (32) . Analysis of the colonic mucus barrier using methacarn-fixed samples [ fig. S4 and (31, 33) ] revealed a significant (P < 0.0001) reduction of the mucus layer after homozygous or heterozygous loss of IEC Pdcd10 at P21 (Fig. 4 , A and C). In contrast, loss of IEC Krit1, Ccm2, or Map3k3 had no effect on mucus layer dimensions at P21 (Fig. 4 , B and D, and figs. S5 and S6). In addition, loss of IEC PDCD10 was associated with markedly swollen goblet cells ( Fig. 4A and fig. S7A ) but no change in the expression of Muc2 mRNA or Mucin-2 (MUC2) protein ( fig. S7 , C to F), whereas loss of IEC Krit1 was not associated with any change in goblet cell vesicle size ( Fig. 4B and fig. S7B ).
VilCre;Pdcd10 fl/+ and VilCre;Pdcd10 fl/fl animals exhibited increased concentration of fecal lipocalin-2 (LCN2 aka NGAL), a secreted inflammatory response protein that has been shown to be a sensitive and dynamic marker of colitis ( Fig. 4E ) (34) that was not observed after IEC loss of Krit1, Ccm2, or Map3k3 (Fig. 4F and figs. S5 and S6). Consistent with the rise in fecal LCN2, P21 iBECre;VilCre;Pdcd10 fl/+ and iBECre;VilCre;Pdcd10 fl/fl colons exhibited crypt dilation, an early sign of inflammation ( Fig. 4A and fig. S7G ), and crypt abscesses marked by lymphocyte antigen 6 complex, locus G (Ly6G)-positive neutrophils (Fig. 4 , G and I). In contrast, P21 iECre;VilCre;Krit1 fl/fl animals exhibited normal colonic crypts without crypt abscesses ( Fig. 4, B , H, and J, and fig. S7H ).
Our prior studies have demonstrated that the amount of circulating LPS determines CCM formation in mouse models, suggesting that loss of gut barrier function associated with IEC PDCD10 deficiency might augment CCM formation by permitting more translocation of GNB-derived LPS from the gut lumen to the circulating blood (20) . Consistent with such a mechanism, loss of IEC PDCD10 resulted in elevated TLR4 agonist activity in circulating blood from P21 animals (Fig. 4K) . In contrast, loss of IEC KRIT1 had no effect on TLR4 agonist activity in circulating blood from P21 animals ( Fig. 4L ). An increase in blood TLR4 activation was not detected in animals with heterozygous loss of IEC Pdcd10 (iBECre;VilCre; Pdcd10 fl/+ ), most likely because of a low basal rate of leak/translocation and the limited sensitivity of measuring circulating LPS at a single time point compared with growth of CCM lesions over 21 days (Fig. 4K ).
Genetic loss of colonic mucus accelerates CCM formation in mice
The studies described above suggested that a primary mechanism by which PDCD10 deficiency in IECs might accelerate CCM formation is through loss of the mucus layer that prevents GNB from reaching the gut wall and translocating to the blood (31) (32) (33) (35) (36) (37) . To directly test the role of the mucus layer in CCM formation, we examined the effect of loss of MUC2, a glycoprotein secreted by goblet cells that is the primary constituent of the colonic mucosal barrier (33, 37) , on lesion formation after Pdcd10 gene deletion in brain endothelial cells at P1. Loss of one or two Muc2 alleles conferred a dose-dependent decrease in both the mucus layer and CCM lesion volume of P21 animals similar to those observed after loss of one or two Pdcd10 alleles in IECs (Fig. 5, A to D) .
The CCM proteins, particularly KRIT1, have been implicated in the maintenance of endothelial junctions, and epithelial junction integrity is another component of the gut barrier underlying colonic mucus (38, 39) . Loss of gut epithelial PDCD10 resulted in decreased E-cadherin (CDH1) but increased epithelial cell adhesion molecule (EpCAM) junction continuity and no changes in F-actin or zonula occludens-1 (ZO-1), whereas loss of gut epithelial KRIT1 did not affect junctions (figs. S8, A to D; S9, A to D; and S10). Muc2-null colons exhibited decreased E-cadherin and EpCAM junction continuity, but Muc2 heterozygous colonic epithelial junctions were unchanged (figs. S8, E and F, and S9, E and F). Thus, Muc2 heterozygosity worsens CCM burden in the setting of a decreased colonic mucus barrier but unchanged epithelial junctions. Overall, these findings suggest that a primary mechanism by which Pdcd10 prevents CCM formation in IECs is through its role in maintaining the colonic mucus layer.
The gut barrier can regulate CCM formation independent of the gut microbiome
In addition to providing a protective layer for the intestinal epithelium, the abundant glycoprotein MUC2 serves as a food source for luminal bacteria and affects microbial ecology (40) . Moreover, MUC2 secretion by goblet cells is bacterial-ligand dependent and affected by qualitative differences in the gut microbiome (36, 41) . Thus, changes in mucus expression could affect CCM formation through changes in the gut microbiome and the gut barrier. To address the relationship between the gut barrier and the gut microbiome, we next performed 16S rRNA gene sequencing of bacterial DNA extracted from the feces of mice with genetic loss of epithelial Pdcd10, Krit1, or Muc2. Because cage and litter effects are a confounding factor in gut microbiome studies (42), we collected fecal pellets from P21 animals before weaning when the entire litter remained cohoused (Fig. 6A) , and all analyses were performed considering individual cage effects ( fig. S11) . A PERMANOVA test of unweighted UniFrac distances revealed a separation of bacterial microbiome communities from VilCre;Pdcd10 fl/fl mice compared with either VilCre;Pdcd10 fl/+ or Pdcd10 fl/fl littermates ( Fig. 6B and figs. S11A and S12A). A similar separation was observed when iBECre;VilCre;Pdcd10 fl/fl animals were compared with iBECre;VilCre;Pdcd10 fl/+ or iBECre;Pdcd10 fl/fl littermates ( Fig. 6C and figs. S11B and S12B). A significant (P < 0.001) separation of bacterial microbiome communities was also observed between iBECre;Pdcd10 fl/fl ;Muc2 −/− when compared to either iBECre; Pdcd10 fl/fl ; Muc2 +/− or iBECre;Pdcd10 fl/fl ;Muc2 +/+ littermates ( Fig. 6D and figs. S11C and S12C). In contrast, no significant (P = 0.311) separation of bacterial microbiome communities was observed between Krit1 fl/fl and VilCre;Krit1 fl/fl animals ( Fig. 6E and figs. S11D and S12D). Fitting generalized, linear mixed-effects models for logit-transformed relative abundances of commonly present bacterial taxa identified almost identical shifts for VilCre;Pdcd10 fl/fl , iBECre; VilCre;Pdcd10 fl/fl , and iBECre;Pdcd10 fl/fl ;Muc2 −/− animals, including a significant (q ≤ 0.05) increase in Bacteroides and Rikenellaceae species and decrease in s24-7, Prevotellaceae, and Alloprevotella species ( Fig. 6F and fig. S13 ). The observation that loss of gut epithelial Pdcd10 conferred biome changes indistinguishable from those associated with loss of Muc2 provides additional evidence that a major effect of IEC PDCD10 loss is disruption of the colonic mucosal barrier composed of MUC2. Analysis of heterozygous VilCre;Pdcd10 fl/+ , iBECre;VilCre;Pdcd10 fl/+ , and iBECre;Pdcd10 fl/fl ;Muc2 +/− animals revealed no significant (q > 0.05) changes in the gut microbiome ( Fig. 6G) , although iBECre;Pdcd10 fl/fl ; Muc2 +/− animals exhibited increased CCM formation. These findings support the conclusion that changes in gut barrier may influence CCM formation independent of changes in the gut microbiome.
The dietary emulsifier P80 degrades colonic mucus and accelerates CCM formation in mice
The studies of DSS exposure and IEC loss of PDCD10 and MUC2 described above suggested that dietary agents that reduce the colonic mucosal barrier may accelerate CCM disease. A recent study reported that dietary emulsifiers, such as those commonly found in processed foods, promote colitis by degrading the colonic mucosal barrier (43) . To test whether ingestion of a common dietary emulsifier might drive CCM formation through changes in the gut barrier, we first exposed Pdcd10 +/− animals to oral 1% P80 emulsifier for 2 weeks and assessed iBECre; the thickness of the colonic mucus layer. P80 emulsifier exposure resulted in a 50% reduction in the mucus layer (Fig. 7, A and B ). 16S rRNA gene sequencing of bacterial DNA extracted from the feces of Pdcd10 +/− mice treated with P80 or vehicle alone revealed that chronic emulsifier exposure did not result in a significant (P > 0.05) separation of bacterial microbiome communities when accounting for cage effects (Fig. 7, C and D, and fig. S14 ). We next assessed whether chronic exposure to DSS could affect CCM formation. Although aged Krit1 +/− animals exhibited no detectable lesion formation after 6 months (Fig. 7, E and G) , aged Pdcd10 +/− animals exhibited a low but significant (P < 0.01) rate of spontaneous lesion formation (Fig. 7, F and G) . Chronic treatment of Pdcd10 +/− animals with 1% P80 significantly (P < 0.05) increased lesion formation (Fig. 7, F and G) . These studies suggest that emulsifiers commonly found in preserved or processed foods may exacerbate CCM formation through effects on the gut mucosal barrier that are independent of the gut microbiome.
Dexamethasone potently inhibits CCM formation through dual effects on brain endothelial cells and gut epithelial cells
The studies described above and our prior studies (20) identify a gut-brain CCM disease axis in which PDCD10 functions in both IECs and brain endothelial cells to control the movement of LPS from the gut lumen into the blood and the response to blood-borne LPS in the brain. This model predicts that therapies able to simultaneously increase gut barrier function by IECs and reduce TLR4-MEKK3-KLF2/4 signaling by brain endothelial cells might potently inhibit CCM formation. Glucocorticoids confer pleiotropic cell and organ effects that are primarily mediated by gene expression changes downstream of glucocorticoid receptor (GR) NR3C1 signaling (44) . Loss of GR function confers increased responses to LPS in endothelial cells (45, 46) , whereas the glucocorticoid dexamethasone increases MUC2 expression by IECs (47), suggesting that dexamethasone, a highly selective GR agonist (48) , might act at both ends of the CCM gut-brain disease axis to prevent lesion formation. A single dose of dexamethasone administered at P5 entirely blocked CCM formation in both iECre;Krit1 fl/fl and iECre;Pdcd10 fl/fl neonates (Fig. 8, A to C, and  fig. S15, A to E) . The effect of dexamethasone blocked lesion formation using a single dose as low as 0.4 mg/kg (Fig. 8A) , less than that commonly administered for asthma exacerbations in human patients. Analysis of brain endothelial gene expression revealed marked reductions in the mRNA transcripts of Map3k3 (Mekk3) as well as the downstream MEKK3 targets Klf2 and Klf4 and the upstream MEKK3 activators Tlr4 and Cd14 after dexamethasone administration (Fig. 8D) .
To test whether rescue was mediated by changes in brain endothelial cells, the effect of dexamethasone was examined in iECre;Krit1 fl/fl ;Nr3c1 fl/fl animals in which endothelial loss of KRIT1 is accompanied by endothelial loss of GR. Dexamethasone treatment continued to potently prevent lesion formation in iECre;Krit1 fl/fl ;Nr3c1 fl/fl animals (Fig. 8, E and F) , indicating that the effect of dexamethasone was not merely due to effects in brain endothelial cells. Analysis of the intestine of dexamethasone-treated animals revealed marked colonic dilatation ( fig. S15E ) that was accompanied by a large increase in goblet cell activity and MUC2 production (Fig. 8, G and H,  and fig. S15, F to H) . The increase in mucus production stimulated by dexamethasone was ablated in VilCre;Nr3c1 fl/fl animals (fig. S15, I and J), indicating that it is mediated by stimulation of IEC GR. To test whether dexamethasone rescue of CCM formation is mediated primarily by effects on IEC mucus production, we examined rescue in mice lacking MUC2. Dexamethasone potently prevented lesion formation in iBECre;Pdcd10 fl/fl ;Muc2 −/− animals (Fig. 8, I to K) , indicating that rescue was also not merely due to effects on IECs. To test whether the potent dexamethasone effect was due to dual action in (Fig. 8L ), but dexamethasone-treated iECre;VilCre;Krit1 fl/fl ; Nr3c1 fl/fl animals developed robust lesion formation similar to those given vehicle only (Fig. 8, M and N) . Although we cannot exclude effects of dexamethasone on the gut microbiome, effects of dexamethasone on other cell types such as immune cells, or the possibility that rescue is mediated solely by GR signaling in IECs, the potent ability of dexamethasone to block CCM formation is most readily explained by dual effects on brain endothelial cell signaling and IEC gut barrier formation. These studies suggest that pharmacologic targeting of multiple sites in a gut-brain axis disease mechanism may yield powerful therapeutic strategies (fig. S15, K and L).
DISCUSSION
A central molecular component of the gut-brain axis in CCM disease identified by these studies is the colonic mucus barrier that physically separates GNB in the colon from the epithelial cell layer and underlying blood vessels of the host. Loss of Pdcd10 in gut epithelial cells resulted in a dose-dependent reduction in the thickness of the colonic mucus layer that correlated with an increase in CCM lesion formation.
The changes in mucus layer thickness and CCM formation conferred by loss of IEC Pdcd10 were replicated by dose-dependent loss of Muc2.
A causal relationship between IEC Pdcd10 and formation of the mucus barrier was further supported by nearly identical changes in gut microbial taxa abundance observed upon loss of Pdcd10 or Muc2. These findings suggested that PDCD10 regulation of mucus production by goblet cells was a likely mechanism for its role in gut epithelial cells in CCM disease. Histologic analysis of the VilCre;Pdcd10 fl/fl colon revealed abnormal, swollen goblet cells that contained large amounts of mucin despite the loss of the extraepithelial mucus barrier. Moreover, quantitative polymerase chain reaction and Western blot analysis of colonic epithelium demonstrated preserved total MUC2 mRNA and protein content in the colons of VilCre;Pdcd10 fl/+ and VilCre;Pdcd10 fl/fl animals. Together, these findings are consistent with a requirement for PDCD10 during mucus secretion rather than MUC2 expression. Our findings provide an explanation for the clinical observation that germline haploinsufficiency of PDCD10 confers a more aggressive disease phenotype than germline haploinsufficiency of KRIT1 or CCM2. Furthermore, they suggest that PDCD10 functions independently of the CCM complex in gut epithelial cells. Consistent with this observation, we found that gut epithelial loss of MEKK3, the kinase regulated by the CCM complex to prevent CCM formation by brain endothelial cells, also does not result in any change in the gut barrier. How does PDCD10 function to regulate the gut barrier? PDCD10 is a component of striatin-interacting phosphatase and kinase (STRIPAK) complexes that do not include KRIT1 or CCM2 and are not known to target MEKK3 (49) . Moreover, PDCD10 has recently been found to participate in vesicle exocytosis in mammalian cells (50, 51) and vesicle trafficking in Caenorhabditis elegans (52) . Thus, although future studies are required to fully define the role of PDCD10 in gut epithelial cells, a mechanism in which PDCD10 functions as part of the STRIPAK but not CCM complex to regulate mucin secretion by goblet cells seems likely.
We acknowledge three main limitations regarding these findings. First, we cannot exclude the possibility that unique PDCD10 signaling in endothelial cells contributes to increased disease severity, although we demonstrated that the primary mechanism of lesion formation is gain of brain endothelial MEKK3 signaling (51) . Second, although we showed in a variety of contexts that the gut barrier can affect CCM severity independently of the gut microbiome, these entities are so complex and intertwined that precisely parsing their individual effects is difficult. Third, this study was performed in mouse models; therefore, translation to human disease remains unproven. Our study illustrates the need to consider both the gut microbiome and barrier when assessing CCM disease risk in patients.
Can our findings be translated to improve the treatment and management of patients with CCM? First, proposed pharmacologic therapies for CCM disease must consider potential effects on gut barrier function. Drugs that adversely affect the gut barrier would be contraindicated, particularly as a chronic, lifelong therapy. Second, our studies of Pdcd10 +/− animals with oral P80 intake confirm prior reports that such agents can reduce the colonic mucus barrier and suggest that common dietary factors such as emulsifiers in processed foods may have a relevant impact on CCM disease course through deleterious effects on the gut barrier. Third, exacerbation of CCM formation by DSS, commonly used to model inflammatory bowel disease in mice, suggests that gastrointestinal conditions associated with chronic inflammation, such as inflammatory bowel disease, are likely to accelerate CCM formation through effects on the gut barrier. Conversely, conditions that increase mucus production and/or reduce gut inflammation would be predicted to slow CCM disease progression.
Last, defining a gut-brain disease axis at the molecular and cellular levels enables the design of therapies to treat diseases refractory to conventional, "on-site" strategies. We have modeled such a therapeutic approach through analysis of an unexpectedly potent glucocorticoid treatment for CCM disease in mice. Genetic dissection of the dexamethasone mechanism of action to prevent CCM formation revealed that the drug acted through GRs in two cell types: brain endothelium and gut epithelium. Thus, the basis for dexamethasone's potency was most likely the fact that it targeted multiple key molecular and cellular mechanisms in the CCM gut-brain axis. Analogous single or multiple drug strategies designed to disable well-defined gutbrain axes may yield potent therapeutic strategies for other such pathologies in the future.
MATERIALS AND METHODS
Study design
As previously described (20) , our lab has extensive experience with the P10 neonatal CCM mouse model. Sample sizes were estimated on the basis of our previous experience with the neonatal CCM model and lesion volume quantitation by blinded microCT, and our sample size calculations were previously detailed. Briefly, at P10, seven animals in each group would be expected to sufficiently power a study at 80% ( = 0.2) at a significance level of  = 0.05, assuming an expected effect size of 80%, equal SDs, and normal distributions. For the P21 neonatal CCM model, we collected 20 brains at P21 and calculated a mean of 0.4 and an SD of 0.2. On the basis of our initial experience with DSS colitis in Fig. 2 (C and D) , we assumed an effect size of 50%. Thus, each group would require 16 animals to power a study at 80% ( = 0.2) with a significance level of  = 0.05, assuming equal SDs and normal distributions. No data inclusion/exclusion or end point criteria were predefined or applied. No outliers were defined or excluded. Each experiment was performed at least twice with different litters and n greater than or equal to three (see specifics in each figure legend).
Research objectives were to define the role of the gut barrier in CCM severity using genetically engineered mouse models. We hypothesized that defects in the gut barrier would increase disease severity and that the clinical aggressiveness of PDCD10 familial disease is caused by defects in gut barrier due to a unique role for PDCD10 in the intestinal epithelium. Research subjects included human patients with CCM and primarily genetically engineered mouse models. All experimental and control animals were littermates, and none were excluded from analysis at the time of harvest. Experimental animals were lost or excluded at two predefined points: (i) failure to properly inject 4-hydroxytamoxifen (4OHT) and observation of substantial leakage and (ii) death before P10 or P21 due to 4OHT injection or drug administration or other unknown causes. Given the early time points before weaning or sexual maturity, no attempt was made to distinguish or segregate results based on gender. Prior studies have found that adult animals heterozygous for CCM genes did not exhibit any difference in lesion burden with respect to gender (53, 54) , so no attempt was made to distinguish genders of animals used in adult CCM experiments.
Blinding was performed at multiple points during the experiments. Induction of the neonatal disease model was performed at 1 day of birth without knowledge of genotypes. MicroCT lesion volume quantification was performed in a blinded manner by investigators without knowledge of experimental details. 16S rRNA gene sequencing of both mouse and human samples were performed in blinded fashion until final analysis.
Statistics
As indicated in the specific figure legends, the SEM, 95% confidence interval, or boxplot is shown. Column data for each experiment were subjected to D'Agostino-Pearson normality tests, and only the P80 emulsifier experiments did not satisfy this test. We also found that in almost all experiments, the variance between groups was significantly (P < 0.05) different. Accordingly, we used unpaired, twotailed, Welch's t tests for all two-group analyses, Kruskal-Wallis (nonparametric) one-way analysis of variance (ANOVA) with Dunn's correction for multiple comparisons in multiple-group analyses, or Mann-Whitney nonparametric U tests for experiments that did not satisfy normality tests. Because the Welch's t test underperforms on small sample sizes and variance calculations are meaningless for smaller samples, experiments with groups less than or equal to 10 distinct samples were analyzed using the unpaired, two-tailed Student's t test or one-way ANOVA with Holm-Sidak correction for multiple comparisons. Statistical tests for 16S rRNA gene sequencing analyses are detailed in the prior methods sections, and all significance (P < 0.05 or q < 0.05) tests were corrected for multiple comparisons using Bonferroni or Benjamini-Hochberg methods.
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